Taztia Xt

Angina Pectoris, Variant, Atrial Fibrillation, Proteinuria + 11 more

Treatment

6 FDA approvals

20 Active Studies for Taztia Xt

What is Taztia Xt

Diltiazem

The Generic name of this drug

Treatment Summary

Diltiazem is a medication used to treat high blood pressure, heart conditions, and chest pain. It is a type of calcium channel blocker that works by preventing calcium from entering the cells of the heart and blood vessels, causing them to relax and widening the vessels. Diltiazem is available in both oral and intravenous forms and can be taken long-term to treat chronic conditions. It is most commonly used to treat hypertension, chronic stable angina, and atrial fibrillation or flutter. It may also be used off-label to treat anal fissures, migraine prevention, pulmonary hypertension, and muscle cramps

Cardizem

is the brand name

Taztia Xt Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Cardizem

Diltiazem

1982

656

Approved as Treatment by the FDA

Diltiazem, commonly known as Cardizem, is approved by the FDA for 6 uses which include Coronary Vasospasm and Coronary Artery Vasospasm .

Coronary Vasospasm

Helps manage Coronary Artery Vasospasm

Coronary Artery Vasospasm

Helps manage Coronary Artery Vasospasm

Anginal Pain

Helps manage Anginal Pain

Hypertensive disease

Helps manage High Blood Pressure (Hypertension)

Angina, Stable

Helps manage Chronic Stable Angina Pectoris

Angina Pectoris

Helps manage Anginal Pain

Effectiveness

How Taztia Xt Affects Patients

Diltiazem works by relaxing the blood vessels and reducing blood pressure. Lowering blood pressure helps to reduce the risk of stroke, heart attack, and other cardiovascular issues. Diltiazem inhibits the flow of calcium into cells, leading to a decrease in heart rate and force of heartbeats. This can help to slow down an abnormally fast heart rate. In people with high blood pressure, taking diltiazem can lower diastolic blood pressure by 1.9, 5.4, 6.1, or 8.6 mmHg depending on the dose taken. In those with angina, diltiaz

How Taztia Xt works in the body

Diltiazem works by blocking slow calcium channels in the heart muscle, which helps reduce calcium levels. This results in the relaxation of smooth muscle and blood vessels, increasing oxygen supply to the heart, lowering blood pressure and afterload, and reducing the heart rate. This decreased stress on the heart can help those with chronic stable angina exercise with greater tolerance.

When to interrupt dosage

The instructed dosage of Taztia Xt is contingent upon the diagnosed condition, for example prophylaxis of migraine headaches, Fissure;Anal and Anginal Pain. The quantity of dosage is determined by the manner of administration, as indicated in the table beneath.

Condition

Dosage

Administration

Angina Pectoris

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Atrial Fibrillation

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Coronary Vasospasm

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Angina Pectoris, Variant

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Proteinuria

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Hypertensive disease

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Angina, Stable

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Tachycardia, Supraventricular

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Cardiomyopathy, Dilated

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Migraine Disorders

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Diabetic Neuropathy

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Pulmonary Hypertension

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Fissure in Ano

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Muscle Cramp

, 120.0 mg, 180.0 mg, 240.0 mg, 300.0 mg, 360.0 mg, 420.0 mg, 100.0 mg, 60.0 mg, 90.0 mg, 30.0 mg, 5.0 mg/mL, 1.0 mg/mL, 0.83 mg/mL

, Tablet, extended release, Oral, Tablet, extended release - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Injection, Injection - Intravenous, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Injection, solution - Intravenous, Injection, solution, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution - Intravenous

Warnings

Taztia Xt has ten contraindications and should not be utilized simultaneously with any of the conditions listed in the following table.

Taztia Xt Contraindications

Condition

Risk Level

Notes

Heart Attack

Do Not Combine

accessory bypass tract

Do Not Combine

accessory bypass tract

Do Not Combine

Bradycardia

Do Not Combine

Ventricular Tachycardia

Do Not Combine

Bradycardia

Do Not Combine

Atrioventricular Block

Do Not Combine

Pulmonary Congestion

Do Not Combine

Shock, Cardiogenic

Do Not Combine

Hypotension

Do Not Combine

There are 20 known major drug interactions with Taztia Xt.

Common Taztia Xt Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Diltiazem.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Diltiazem.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Diltiazem.

Alfentanil

Major

The metabolism of Alfentanil can be decreased when combined with Diltiazem.

Amifostine

Major

Diltiazem may increase the hypotensive activities of Amifostine.

Taztia Xt Toxicity & Overdose Risk

The toxic dose of diltiazem in mice is between 415-740mg/kg and 560-810mg/kg in rats. Dogs have been found to have a safe dose of over 50mg/kg and 360mg/kg in monkeys has been found to be fatal. Overdoses of diltiazem, which range from less than 1g to 18g, can cause slow heart rate, low blood pressure, heart block, and cardiac failure. Treatment for overdose includes supportive measures and decontamination of the gastrointestinal system. Atropine, isoproterenol, fluids, vasopressors, and in

image of a doctor in a lab doing drug, clinical research

Taztia Xt Novel Uses: Which Conditions Have a Clinical Trial Featuring Taztia Xt?

At present, 228 active clinical trials are being conducted to assess the utility of Taztia XT for treating Atrial Fibrillation, Coronary Artery Spasm and Paroxysmal Supraventricular Tachycardia (PSVT).

Condition

Clinical Trials

Trial Phases

Atrial Fibrillation

90 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 1, Phase 3, Early Phase 1

Diabetic Neuropathy

6 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Pulmonary Hypertension

33 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1

Tachycardia, Supraventricular

2 Actively Recruiting

Phase 3, Phase 2

Angina, Stable

0 Actively Recruiting

Angina Pectoris, Variant

0 Actively Recruiting

Angina Pectoris

2 Actively Recruiting

Not Applicable, Phase 4

Cardiomyopathy, Dilated

1 Actively Recruiting

Not Applicable

Proteinuria

5 Actively Recruiting

Phase 2, Phase 3, Phase 4, Phase 1

Muscle Cramp

0 Actively Recruiting

Hypertensive disease

27 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Coronary Vasospasm

0 Actively Recruiting

Migraine Disorders

1 Actively Recruiting

Phase 3

Fissure in Ano

0 Actively Recruiting

Taztia Xt Reviews: What are patients saying about Taztia Xt?

5

Patient Review

4/5/2012

Taztia Xt for Ventricular Rate Control in Atrial Fibrillation

I stopped taking Taztia XT because it was causing me to experience dizziness and severe hallucinations.

5

Patient Review

11/18/2008

Taztia Xt for High Blood Pressure

5

Patient Review

6/18/2010

Taztia Xt for High Blood Pressure

I haven't had any issues while taking this medication, and I'm really pleased with it!

5

Patient Review

9/24/2011

Taztia Xt for High Blood Pressure

The treatment made me dizzy and affected my vision.

4.7

Patient Review

10/1/2013

Taztia Xt for High Blood Pressure

I've been taking this medication for years at the insistence of my doctor, and while it does help lower my blood pressure, the side effects are not worth it. Dizziness, blurred vision, fatigue, and general malaise are all common complaints I have. Additionally, heat really bothers me when I'm on this medication.

4.7

Patient Review

12/6/2014

Taztia Xt for High Blood Pressure

I'm mostly pleased with this medication. I have dealt with occasional dizzy spells, but it's a small price to pay for having lower blood pressure and pulse rate.

4.7

Patient Review

9/19/2008

Taztia Xt for High Blood Pressure

4

Patient Review

1/27/2010

Taztia Xt for High Blood Pressure

3.7

Patient Review

1/10/2013

Taztia Xt for High Blood Pressure

This has been successful in keeping my blood pressure within a normal range. I feel much better as a result.

3

Patient Review

5/22/2015

Taztia Xt for High Blood Pressure

While this medication has been effective in lowering my blood pressure, I have experienced debilitating leg pain as a side effect. This pain has made it difficult to walk or stand for long periods of time, and is likely due to calcium deficiency caused by the drug.

3

Patient Review

8/21/2013

Taztia Xt for High Blood Pressure

It's frustrating that this treatment takes a while to work and only lasts for 6-8 hours.

3

Patient Review

4/8/2013

Taztia Xt for Ventricular Rate Control in Atrial Fibrillation

I initially gained a lot of weight suddenly, and my blood pressure became uncontrolled as a result. I started taking this medication alongside Quinapril, which helped to get my BP under control. However, I've since lost 85lbs and my BP is now below normal (110/70) even without the medication. It's probably time to reduce my dosage of Quinapril as well.

3

Patient Review

11/15/2011

Taztia Xt for High Blood Pressure

I'm not sure this treatment has done much for me. I was shocked into sinus rhythm in Sept, but since then my heart rate has been increased and I've gained a pound per week. On top of that, now I'm itching all the time.

2.3

Patient Review

8/14/2013

Taztia Xt for High Blood Pressure

I've been on this medication for around twelve months now, and I haven't seen much success. However, it does help to lower my heart rate.

2.3

Patient Review

12/23/2008

Taztia Xt for Ventricular Rate Control in Atrial Fibrillation

2

Patient Review

10/21/2008

Taztia Xt for High Blood Pressure

1.3

Patient Review

9/9/2016

Taztia Xt for High Blood Pressure

Blurry vision and severe pain in lower extremities were just a couple of the issues I experienced while taking this medication. Additionally, it didn't really do much to help my blood pressure. Needless to say, I stopped taking it as soon as possible.

1

Patient Review

2/5/2010

Taztia Xt for High Blood Pressure

This medicine effectively controls my irregular heartbeat.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about taztia xt

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Cartia XT the same as Cardizem CD?

"Diltiazem (Cartia XT, Cardizem CD) is an oral medication used to treat high blood pressure and angina. It is taken once or twice daily."

Answered by AI

What is Taztia XT used for?

"Diltiazem is used to lower high blood pressure and prevent chest pain. Reducing high blood pressure helps to avoid strokes, heart attacks, and kidney problems. With regular use, diltiazem can decrease the number and severity of episodes of chest pain caused by angina."

Answered by AI

What is the drug diltiazem used to treat?

"If you have high blood pressure, diltiazem can help prevent heart disease, heart attacks, strokes, and chest pain caused by angina. It can also help heal an anal fissure."

Answered by AI

Is Taztia the same as diltiazem?

"Taztia Xt is also occasionally used to treat arrhythmias (irregular heartbeats).

The prescription medication Taztia Xt is used to treat hypertension (high blood pressure) and chest pain caused by angina. Taztia Xt is the brand-name drug and diltiazem is its generic version. Taztia Xt is also occasionally used to treat arrhythmias (irregular heartbeats)."

Answered by AI

Clinical Trials for Taztia Xt

Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Image of Northwestern University in Chicago, United States.

Exercise Program for Atrial Fibrillation and Heart Failure

60 - 99
All Sexes
Chicago, IL

Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) are very common conditions that often occur together and result in worsening symptoms and reduced quality of life (QoL). Limitations being able to participate in activities of daily living is a primary complaint for AF-HFpEF patients, yet effective strategies to address this issue remain limited. While exercise interventions targeting aerobic training (AT) are recommended for patients with AF and HFpEF, unique challenges exist in this patient population who tend to be older. Specifically, many older patients with AF and HFpEF have muscle weakness, sarcopenia and frailty, that can make aerobic-focused exercise difficult and less tolerable. This study proposes that starting with progressive resistance training (PRT) before aerobic exercise may overcome these issues by improving muscle strength, making AT more manageable, and leading to better health outcomes. The goal of this study is to assess whether a sequential exercise program, named 'PREACTIVE' improves how people feel, decrease the amount of symptoms, and their ability to participate in exercise and activities. This study will specifically test a sequenced exercise approach of resistance training followed by aerobic exercise to improve symptoms, and quality of life in AF-HFpEF.

Waitlist Available
Has No Placebo

Northwestern University

Deepika Laddu, PhD

Image of the FSU TMH Family Practice Residency Program in Tallahassee, United States.

Cannabidiol for Diabetic Neuropathy

40 - 70
All Sexes
Tallahassee, FL

The "Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot study (CBD-DPN1)" is a double-blinded, placebo-controlled, crossover pilot study evaluating the efficacy of Cannabidiol (CBD) and full-spectrum CBD (fsCBD) tinctures in treating Diabetic Peripheral Neuropathy (DPN)-associated pain. DPN is a common, highly distressing complication of diabetes, characterized by chronic pain and loss of sensory function, for which currently available treatments primarily offer only symptomatic relief. CBD and fsCBD are being investigated for their potential neuroprotective and analgesic effects by regulating inflammation and oxidative stress. The study aims to recruit 12 to 20 adult participants who have mild to moderate DPN. Subjects will receive either an active treatment (CBD isolate or fsCBD in MCT oil, dosed at 50 mg twice daily for a total of 100 mg daily) or a placebo during two sequential 6-week phases. The overall objective of this pilot phase is primarily methodological: to test and refine the clinical protocol, assess patient compliance and acceptability of the CBD formulations, and generate sufficient data to calculate the necessary sample size for a larger, definitive study. Efficacy will be measured using objective and subjective metrics, including DPN severity (DN4 Assessment Tool and DPNCheck™ for nerve conduction velocity) and pain level (PainDetect Questionnaire). Secondary outcomes include evaluating mood (HADS), sleep quality (MOS Sleep Scale), and quality of life (EQ-5D-5L).

Phase 1 & 2
Waitlist Available

the FSU TMH Family Practice Residency Program

Have you considered Taztia Xt clinical trials?

We made a collection of clinical trials featuring Taztia Xt, we think they might fit your search criteria.
Go to Trials
Image of Grand Island Pain Relief Center in Grand Island, United States.

BurstDR Spinal Cord Stimulation for Diabetic Neuropathy

18+
All Sexes
Grand Island, NE

This prospective, single-arm clinical study evaluates the therapeutic efficacy and feasibility of BurstDR spinal cord stimulation (SCS) using Abbott's Proclaim XR and Eterna systems in patients with painful diabetic neuropathy (PDN). Adults with confirmed PDN will undergo a one-week temporary SCS trial, and those achieving meaningful improvement (≥50% reduction in average pain on the Visual Analog Scale) will proceed to permanent implantation. Outcomes will be assessed at baseline, end of trial, and at 1-, 3-, and 6-month follow-up visits using validated instruments including VAS, DN4, DQoL, PSQ-3, the Patient Global Impression of Change, and the Clinician Global Impression of Change. All procedures follow standard clinical practice for SCS therapy. The study aims to characterize real-world effectiveness, patient-reported outcomes, feasibility of implementation, and device-related safety in a rural PDN population.

Waitlist Available
Has No Placebo

Grand Island Pain Relief Center

TriCity Research Center

Image of Inova Alexandria Hospital in Alexandria, United States.

Heparin Dosing for Blood Clots and Heart Conditions

18+
All Sexes
Alexandria, VA

The goal of this clinical trial study is to test whether a mathematical calculation, using the patient's gender, weight and kidney function, can better predict a patient's heparin goal dose than a flat number of units per patient weight can. Participants will have the first dose of heparin infusion calculated, after which if adjustments are needed, the Hospital's prebuilt table for results driven dosing for this purpose is used. The researchers will compare the time it takes for the participants to get to the desired goal using the patient's information for calculation versus patients in the past who received the medication using the flat rate. The hypothesis is that the patients with enhanced personal data, gender, weight and kidney function, included for the initial dose, will get to their goal lab value sooner and with less chance of delay or overshooting the goal. A quicker time to goal lab value is beneficial to patients in many ways, including earlier treatment of the clot or coronary issue that the patient is experiencing.

Phase 4
Waitlist Available

Inova Alexandria Hospital

Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL

This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.

Waitlist Available
Has No Placebo

U Health (+1 Sites)

Ziad Zoghby, M.D., M.B.A.

Biobeat Technologies Ltd.

Have you considered Taztia Xt clinical trials?

We made a collection of clinical trials featuring Taztia Xt, we think they might fit your search criteria.
Go to Trials
Image of UPMC Presybeterian in Pittsburgh, United States.

Telaglenastat for Pulmonary Hypertension

18 - 75
All Sexes
Pittsburgh, PA

The research study is being conducted to evaluate the effectiveness of a drug called Telaglenastat in adults diagnosed with Pulmonary Hypertension (PH). PH is a progressive condition that affects the arteries in the lungs, specifically the pulmonary arteries, which carry blood from the right side of the heart to the lungs. Telaglenastat is not currently approved by the Food and Drug Administration for the treatment of PH. However, the study investigators believe that Telaglenastat may help lower blood pressure in the lungs and improve both heart and lung function. It is important to note that the drug will not be available to participants once the study concludes.

Phase 1 & 2
Waitlist Available

UPMC Presybeterian

Michael Risbano, MD

Have you considered Taztia Xt clinical trials?

We made a collection of clinical trials featuring Taztia Xt, we think they might fit your search criteria.
Go to Trials